Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
 and Lead Plaintiff Deadline - May 28, 2018 - EconoTimes)
NEW YORK, May 02, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Solid Biosciences Inc. ("Solid" or the "Company") (NASADAQ:SLDB) and certain of its officers, on behalf of shareholders who purchased Solid securities (1) in Solid’s initial public offering on or about January 25, 2018; or (2) on the open market from January 25, 2018 through March 14, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/sldb.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Solid’s lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; (2) The company misled investors regarding the toxicity of SGT-001; and (3) consequently, defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects were materially false and/or misleading.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/sldb or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Solid you have until May 28, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
